Hemophilia: Nursing process (ADPIE)

Last updated: February 16, 2026

Hemophilia: Nursing process (ADPIE)

gap test med surg

gap test med surg

Aortic aneurysm: Nursing process (ADPIE)
Coronary artery disease (CAD) and angina pectoris: Nursing process (ADPIE)
Hypertension: Nursing process (ADPIE)
Left-sided heart failure: Nursing process (ADPIE)
Myocardial infarction (MI): Nursing process (ADPIE)
Pericardial effusion and cardiac tamponade: Nursing process (ADPIE)
Rheumatic heart disease: Nursing process (ADPIE)
Antihyperlipidemics - Statins: Nursing pharmacology
Calcium-channel blockers: Nursing pharmacology
Angiotensin II receptor blockers (ARBs): Nursing pharmacology
Angiotensin-converting enzyme (ACE) inhibitors: Nursing pharmacology
Antihyperlipidemics - Miscellaneous: Nursing pharmacology
Diabetes insipidus: Nursing process (ADPIE)
Diabetes mellitus (DM): Nursing process (ADPIE)
Diabetic ketoacidosis (DKA): Nursing process (ADPIE)
Hyperosmolar hyperglycemic state (HHS): Nursing process (ADPIE)
Hyperthyroidism: Nursing process (ADPIE)
Hypothyroidism: Nursing process (ADPIE)
Syndrome of inappropriate antidiuretic hormone (SIADH): Nursing process (ADPIE)
Medications for antidiuretic hormone (ADH) disorders: Nursing pharmacology
Medications for thyroid disorders: Nursing pharmacology
Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics: Nursing pharmacology
Oral antidiabetic medications - Alpha-glucosidase inhibitors: Nursing pharmacology
Oral antidiabetic medications - Biguanides and thiazolidinediones: Nursing pharmacology
Oral antidiabetic medications - DPP-4 inhibitors: Nursing pharmacology
Oral antidiabetic medications - Sulfonylureas and meglitinides: Nursing pharmacology
Oral antidiabetic medications - Sodium-glucose co-transporter-2 (SGLT-2) inhibitors: Nursing pharmacology
Insulin: Nursing pharmacology
Medications for growth hormone disorders: Nursing pharmacology
Epistaxis: Nursing process (ADPIE)
Eye injury: Nursing process (ADPIE)
Glaucoma: Nursing process (ADPIE)
Tonsillitis: Nursing process (ADPIE)
Antiglaucoma medications: Nursing pharmacology
Eye anesthetics: Nursing pharmacology
Mydriatics and cycloplegics: Nursing pharmacology
Ophthalmic anti-inflammatories and anti-infectives: Nursing pharmacology
Appendicitis: Nursing process (ADPIE)
Celiac disease: Nursing process (ADPIE)
Cirrhosis: Nursing process (ADPIE)
Gastroesophageal reflux disease (GERD): Nursing process (ADPIE)
Hiatal hernia: Nursing process (ADPIE)
Pancreatitis: Nursing process (ADPIE)
Peptic ulcer disease (PUD): Nursing process (ADPIE)
Antacids: Nursing pharmacology
Antidiarrheals: Nursing pharmacology
Laxatives: Nursing pharmacology
Weight loss medications: Nursing pharmacology
Antiemetics: Nursing pharmacology
Gallstone-dissolving agents: Nursing pharmacology
Gastric mucosal protective agents: Nursing pharmacology
Antispasmodics (GI): Nursing pharmacology
Histamine H2 antagonists: Nursing pharmacology
Proton pump inhibitors (PPIs): Nursing pharmacology
Treatment for Helicobacter pylori: Nursing pharmacology
Diuretics - Osmotic and carbonic anhydrase inhibitors: Nursing pharmacology
Cholinergic therapy (GU): Nursing pharmacology
Acute kidney injury (AKI): Nursing process (ADPIE)
Benign prostatic hyperplasia (BPH): Nursing process (ADPIE)
Urinary incontinence - Stress: Nursing process (ADPIE)
Urinary tract infections (UTIs): Nursing process (ADPIE)
Hemophilia: Nursing process (ADPIE)
Leukemia: Nursing process (ADPIE)
Sickle cell disease: Nursing process (ADPIE)
Anticoagulants - Heparin: Nursing pharmacology
Antiplatelet agents: Nursing pharmacology
Hemostatics: Nursing pharmacology
Iron preparations: Nursing pharmacology
Thrombolytics: Nursing pharmacology
Antihyperlipidemics - Fibrates: Nursing pharmacology
Blood products: Nursing pharmacology
Antihyperlipidemics - Bile acid sequestrants and cholesterol absorption inhibitors: Nursing pharmacology
Anticoagulants - Direct thrombin and factor Xa inhibitors: Nursing pharmacology
Anaphylaxis: Nursing process (ADPIE)
Lyme disease: Nursing process (ADPIE)
Vaccines: Nursing pharmacology
Immunoglobulins: Nursing pharmacology
Immunosuppressants for autoimmune diseases: Nursing pharmacology
Atopic dermatitis: Nursing process (ADPIE)
Frostbite: Nursing process (ADPIE)
Methicillin-resistant Staphylococcus aureus (MRSA): Nursing process (ADPIE)
Pressure injury: Nursing process (ADPIE)
Debridement agents: Nursing pharmacology
Keratolytics: Nursing pharmacology
Antibiotics - Topical: Nursing pharmacology
Antifungals - Topical: Nursing pharmacology
Corticosteroids - Topical: Nursing pharmacology
Acute compartment syndrome: Nursing process (ADPIE)
Fractures: Nursing process (ADPIE)
Gout: Nursing process (ADPIE)
Musculoskeletal injuries: Nursing process (ADPIE)
Rheumatoid arthritis (RA): Nursing process (ADPIE)
Acetylcholinesterase inhibitors for myasthenia gravis: Nursing pharmacology
Analgesics: Nursing pharmacology
Antiepileptics: Nursing pharmacology
Medications for Alzheimer disease: Nursing pharmacology
Skeletal muscle relaxants: Nursing pharmacology
Medications for migraines: Nursing pharmacology
Meningitis: Nursing process (ADPIE)
Parkinson disease: Nursing process (ADPIE)
Seizure disorder: Nursing process (ADPIE)
Stroke: Nursing process (ADPIE)
Trigeminal neuralgia: Nursing process (ADPIE)
Breast cancer: Nursing process (ADPIE)
Tumor lysis syndrome (TLS): Nursing Process (ADPIE)
Plant extracts for chemotherapy: Nursing pharmacology
Antitumor antibiotics: Nursing pharmacology
Alkylating agents: Nursing pharmacology
Peripheral arterial disease (PAD): Nursing process (ADPIE)
Peripheral venous disease (PVD): Nursing process (ADPIE)
Candidiasis: Nursing process (ADPIE)
Gonorrhea and chlamydia: Nursing process (ADPIE)
Pelvic inflammatory disease (PID): Nursing process (ADPIE)
Asthma: Nursing process (ADPIE)
Bacterial pneumonia: Nursing process (ADPIE)
Carbon monoxide poisoning: Nursing process (ADPIE)
Chronic obstructive pulmonary disease (COPD): Nursing process (ADPIE)
Epiglottitis: Nursing process (ADPIE)
Foreign body aspiration and upper airway obstruction: Nursing process (ADPIE)
Laryngotracheobronchitis (LTB) and croup: Nursing process (ADPIE)
Smoke inhalation injury: Nursing process (ADPIE)
Venous thromboembolism (VTE): Nursing process (ADPIE)
Antihistamines: Nursing pharmacology
Bronchodilators: Nursing pharmacology
Corticosteroids - Inhaled: Nursing pharmacology
Mast cell stabilizers - Inhaled: Nursing pharmacology
Leukotriene modifiers: Nursing pharmacology
Medications to control airway secretions: Nursing pharmacology
Oxygen therapy: Nursing pharmacology

Notes

HEMOPHILIA

KEY POINTS
NOTES
PATIENT REPORT
  • 14-year-old boy
  • Hemophilia type A
  • Fell off skateboard

PATHOPHYSIOLOGY
  • Hemophilia
    • Group of genetic bleeding disorders 
  • Coagulation
    • Tissue injury causes blood vessel constriction to limit blood flow and loss 
    • Platelets adhere to injured vessel to form a plug
    • Coagulation cascade activated
      • Extrinsic pathway
      • Intrinsic pathway
      • Common pathway
  • Risk factors
    • Family history
  • Signs and symptoms
    • Excessive bleeding
    • Easy bruising
    • Cephalohematoma
    • Nosebleeds
    • Muscle hematomas
    • Hemarthrosis
  • Complications
    • Internal bleeding
    • Intracerebral hemorrhaging 

DIAGNOSIS AND TREATMENT
  • Diagnosis
    • History
    • Physical assessment
    • Family history
    • Laboratory tests
    • Genetic testing
  • Treatment
    • Transfusions
    • Antifibrinolytics
    • Desmopressin
    • Lifestyle modifications

ASSESSMENT
  • Fell onto buttocks
  • Pain with sitting, lying on back, unable to put weight on left leg
  • Large ecchymosis on buttocks and hip
  • Warm skin
  • No numbness or tingling
  • Temperature: 98.3 F (36.8 C)
  • Heart rate: 100
  • Respiratory rate: 18
  • Blood pressure: 110/75 mmHg
  • Oxygen saturation: 99% room air
  • Pain: 6/10 
  • aPTT: 70 seconds
  • PT: 12 seconds
  • Platelets: 270,000/mm(270 x109/L)

NURSING DIAGNOSES
  • Bleeding related to impaired coagulation
  • Acute pain related to bleeding into tissues
  • Ineffective health maintenance related to perceived seriousness of condition
  • Impaired physical mobility related to joint pain

PLANNING
  • Controlled bleeding
  • Tolerable pain
  • Verbalize understanding of home management
  • Identify less risky activities 
  • Retain mobility and range of motion

IMPLEMENTATION
  • Immobilize leg
  • Apply pressure and ice
  • Administer medications as prescribed
  • Provide teaching on discharge care
  • Identify when to seek medical attention
  • Recommend physical therapy
  • Urge participation in other sports
  • Demonstrate use of crutches
  • Confirm use of medical alert bracelet 

EVALUATION
  • No further signs of bleeding
  • Swelling has not increased
  • Pain: 3/10
  • Plans to join swimming team
  • Demonstrates use of crutches

Transcript

Watch video only

James West is a 14-year-old male client with a history of hemophilia type A. He was brought to the emergency department, or ED, by his grandmother, Mrs. West, after falling off his skateboard.

James states that he was wearing a helmet and protective pads over his elbows and knees but that he fell onto his buttocks while learning a new skateboarding trick.

He says that it hurts to sit down or bend his left leg at the hip. Hemophilia is a group of genetic bleeding disorders caused by deficiencies in various coagulation factors.

Normally, after a tissue injury, there’s an immediate constriction of the blood vessel to limit the amount of blood flow and loss.

After that, platelets start adhering to the injured vessel wall to form a plug, and the coagulation cascade is activated.

First off in the blood there’s a set of clotting factors, most of which are proteins synthesized by the liver, and usually these are inactive and just floating around the blood.

The coagulation cascade starts when one of these proteins gets activated. This active protein then activates the next clotting factor, and so on.

Now, the coagulation cascade can get started in two ways. The first way is called the extrinsic pathway, and it starts when tissue factor gets exposed by the injury of the endothelium.

The tissue factor turns inactive factor VII into activated factor VIIa. Together, the tissue factor and the newly formed factor VIIa form a complex that turns factor X into active factor Xa.

Factor Xa, with factor Va as a cofactor, turns factor II, also called prothrombin, into factor IIa, also called thrombin.

Thrombin then turns factor I or fibrinogen, into factor Ia or fibrin, which precipitates out of the blood at the site of injury.

On the other hand, the intrinsic pathway starts when platelets near the blood vessel injury activate factor XII into factor XIIa.

Next, factor XIIa activates factor XI to factor XIa, which further activates factor IX to factor IXa.

Finally, factor IXa and factor VIIIa work together to activate factor X to factor Xa, and from that point, both the extrinsic and intrinsic pathways basically converge on a single final path called the common pathway.

Now, the most important risk factor for hemophilia is having a family history of hemophilia; and there are three main types: A, B, and C.

The most common one is hemophilia A, which is caused by mutations of the F8 gene, leading to deficiency of factor VIII; while hemophilia B is caused by mutations in the F9 gene, which leads to deficiency of factor IX.

Both hemophilia A and B are X-linked recessive, so they almost exclusively affect males, while females are only carriers.

On the other hand, hemophilia C is caused by mutations in the F11 gene coding for factor XI, and is an autosomal recessive disorder, meaning it can affect both males and females.

Now, all hemophilias present with the same signs and symptoms. The severity depends on the baseline factor activity, represented as a percentage of normal activity.

Having 5 to 40% of normal factor activity is defined as mild hemophilia and typically presents with excessive bleeding after surgical or dental procedures, as well as heavy menstrual bleeding.

Activity between 1% to 5% refers to moderate hemophilia, which presents with symptoms such as easy bruising, even after very minor trauma.

Finally, activity less than 1% is defined as severe hemophilia and unfortunately, most clients have this form of the disease.

Clinical features associated with severe hemophilia are typically present since birth, and include cephalohematoma, which is bleeding under the scalp due to pressure on the fetal head during delivery; as well as excessive bleeding from circumcision.

Other important clinical features that are commonly seen in clients with hemophilia include nosebleeds, ecchymosis, muscle hematomas, and hemarthrosis, or bleeding within the joint space, which is common in young children once they start walking and falling.

Repeated episodes of hemarthrosis can eventually lead to synovitis and arthropathy, which can be further complicated by joint deformation, leading to restricted range of motion and chronic pain.

Clients affected by hemophilia can also develop some life-threatening complications, such as internal bleeding, which can often be retroperitoneal, gastrointestinal, and urinary.

On some occasions, they can also present with intracerebral hemorrhage, which can result in a stroke or increased intracranial pressure.

Now, diagnosis of hemophilia is usually based on clinical presentation, family history, and lab tests, including a platelet count, which is usually normal, as well as a normal prothrombin time or PT, since the extrinsic pathway is not involved, and a prolonged activated partial thromboplastin time or aPTT, since the intrinsic pathway is affected.

Finally, the hemophilia type can be confirmed via tests to look at specific factor activities, as well as genetic testing to identify the mutated gene.

The treatment of hemophilia includes transfusion of the deficient clotting factor.

Additionally, antifibrinolytics can be used to prevent severe blood loss in surgical procedures or during menstrual bleeding.

Sources

  1. "Ackley and Ladwig’s Nursing Diagnosis Handbook: An Evidence-Based Guide to Planning Care, 13th edition" Mosby (2022)
  2. "Effects of replacement therapies with clotting factors in patients with hemophilia: A systematic review and meta-analysis" PLoS One (2022)
  3. "Harrison’s Principles of Internal Medicine, 21st edition" McGraw Hill / Medical (2022)
  4. "Mortality in congenital hemophilia A - a systematic literature review" J Thromb Haemost (2021)
  5. "Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review" Blood Rev (2021)
  6. "Critical Care Nursing: Diagnosis and Management, 9th edition" Elsevier (2021)
  7. "Health Assessment for Nursing Practice, 7th edition" Elsevier (2021)
  8. "Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis" Blood (2021)